Cisplatin – 50 mg

Brand:
Cayman
CAS:
15663-27-1
Storage:
-20
UN-No:
De Minimis - 3288 / 6.1

Cisplatin is a platinum-containing compound that acts as a DNA-crosslinking agent and interferes with replication and transcription, culminating in apoptosis.{25182} It forms intra- and interstrand crosslinks with DNA with intrastrand guanine-to-guanine or guanine-to-alanine links accounting for the majority of DNA binding.{39782} Cisplatin halts the cell cycle at the G2/M phase in vitro and is active against murine tumors transplanted into mice and in mouse xenograft models, including a reduction in tumor growth in a model of squamous cell carcinoma of the head and neck when administered at doses ranging from 7.5 to 12.5 mg/kg.{39783,39784} Cisplatin also inhibits the RecA recombinase of M. tuberculosis (IC50 = 2 µM), blocking protein splicing and cell growth.{26034} Formulations containing cisplatin have been used, alone and in combination therapy, in the treatment of a variety of cancers.  

 

SKU: - Category:

Description

A DNA-crosslinking agent; halts the cell cycle at the G2/M phase in vitro; active against murine tumors transplanted into mice and in mouse xenograft models; reduces tumor growth in a squamous cell carcinoma mouse xenograft model at doses of 7.5-12.5 mg/kg; inhibits RecA recombinase of M. tuberculosis (IC50 = 2 µM)


Formal name: (SP-4-2)-diamminedichloro-platinum

Synonyms:  cis-Diamminedichloroplatinum|CDDP|Cisplatinum|NSC 119875

Molecular weight: 300.1

CAS: 15663-27-1

Purity: ≥95%

Formulation: A crystalline solid


Product Type|Biochemicals||Research Area|Cancer|Cell Cycle|G2/M||Research Area|Cancer|Cell Death||Research Area|Cancer|DNA Damage and Repair||Research Area|Immunology & Inflammation||Research Area|Infectious Disease|Bacterial Diseases|Tuberculosis